Stack · Promising

interaction matrix

Comprehensive reference for peptide-peptide interactions across healing, growth hormone, cognitive, mitochondrial, immune, sexual health, fat loss, and anti-aging categories. Each pair is rated Synergy / Neutral / Caution / Conflict with reasoning, evidence basis, and protocol notes. --- | # | Stack | Rating | Category | Deep

Last updated · Sun Apr 12

Peptide Interaction Matrix

Comprehensive reference for peptide-peptide interactions across healing, growth hormone, cognitive, mitochondrial, immune, sexual health, fat loss, and anti-aging categories. Each pair is rated Synergy / Neutral / Caution / Conflict with reasoning, evidence basis, and protocol notes.

Quick-Reference: Top Synergy Pairs

#	Stack	Rating	Category	Deep Dive
1	BPC-157 + TB-500	Synergy	Healing	BPC-157-TB-500
2	CJC-1295 + Ipamorelin	Synergy	GH Optimization	CJC-1295-Ipamorelin
3	Semax + Selank	Synergy	Cognitive	Semax-Selank
4	MOTS-c + SS-31 + NAD+	Synergy	Mitochondrial	MOTS-c-SS-31-NAD
5	BPC-157 + KPV	Synergy	Gut Healing	BPC-157-KPV
6	GHK-Cu + Epithalon	Synergy	Anti-Aging	GHK-Cu-Epithalon
7	5-Amino-1MQ + NAD+	Synergy	Metabolic	5-Amino-1MQ-NAD
8	Thymosin Alpha-1 + KPV	Synergy	Immune	Thymosin-Alpha-1-KPV
9	AOD-9604 + 5-Amino-1MQ	Synergy	Fat Loss	AOD-9604-5-Amino-1MQ
10	PT-141 + Kisspeptin	Synergy	Sexual Health	PT-141-Kisspeptin

Quick-Reference: Conflict & Caution Table

Pair	Rating	Risk	Key Concern
BPC-157 + Any (with active cancer)	Conflict	High	Angiogenesis may support tumor vascularization
Epithalon + Any (with active cancer)	Conflict	High	Telomerase activation is a cancer hallmark
GH Secretagogues + Active malignancy	Conflict	High	Elevated IGF-1 promotes tumor growth
CJC-1295/Ipamorelin + MK-677	Caution	Medium	Excessive GH/IGF-1 elevation; insulin resistance risk
CJC-1295/Ipamorelin + GHRP-6	Caution	Medium	GHRP-6 raises cortisol/prolactin; hunger spikes
PT-141 + Melanotan II	Caution	Medium	Overlapping MC4R activation; amplified side effects
TA-1 + Immunosuppressants	Conflict	High	Directly antagonistic mechanisms
MOTS-c + Insulin (without monitoring)	Caution	Medium	Hypoglycemia risk — MOTS-c improves glucose uptake
Multiple GH Secretagogues stacked	Caution	Medium	Supraphysiological GH/IGF-1; acromegaly-like effects
Epithalon + High-dose melatonin	Caution	Low	Potential overshoot of pineal signaling

Full Interaction Matrix by Category

Category 1: Healing Peptides

BPC-157 + TB-500

Rating: Synergy
Reasoning: Complementary tissue repair — BPC-157 drives local growth factor upregulation (VEGF, EGF) and angiogenesis; TB-500 drives systemic cell migration via actin regulation. Together they cover all three healing cascade phases: inflammation, proliferation, remodeling.
Evidence: Extensive individual preclinical data; mechanistic complementarity well-established. No combination RCT. Widespread clinical practice and community consensus. Known as the “Wolverine Stack.”
Protocol Notes: Never mix in same vial. BPC-157: 250-500 mcg/day SubQ (local). TB-500: 2-5 mg/week SubQ (systemic). 8-12 week cycles, 30-day washout. See BPC-157-TB-500.

BPC-157 + GHK-Cu

Rating: Synergy
Reasoning: BPC-157 repairs via growth factor pathways; GHK-Cu remodels extracellular matrix and collagen. Both promote angiogenesis through different upstream signals. Particularly effective for skin wounds, surgical recovery, and tendon repair.
Evidence: Individual compound evidence is strong. No combination studies. Additive angiogenic effects predicted from overlapping downstream targets.
Protocol Notes: BPC-157: 250-500 mcg/day SubQ. GHK-Cu: 1-2 mg/day SubQ or topical. Can run simultaneously. Monitor for excessive angiogenesis in cancer-risk individuals.

TB-500 + GHK-Cu

Rating: Synergy
Reasoning: TB-500 mobilizes cells toward injury; GHK-Cu provides the ECM scaffolding and growth signals at the destination. Complementary temporal phases of wound healing.
Evidence: Individual preclinical data. No combination data. Mechanistic synergy is logical.
Protocol Notes: Standard doses of each. TB-500: 2-5 mg/week. GHK-Cu: 1-2 mg/day. No timing conflicts.

BPC-157 + KPV

Rating: Synergy
Reasoning: BPC-157 rebuilds gut tissue; KPV suppresses NF-kB-driven inflammation causing the damage. Addresses both cause and consequence of gut pathology. Gold-standard gut healing combination.
Evidence: Both have individual preclinical IBD model data. Commercial combo capsules available. Strong clinical practice consensus. See BPC-157-KPV.
Protocol Notes: Oral capsules preferred for gut targeting. 250-500 mcg BPC-157 + 500 mcg-1 mg KPV daily. 8-12 weeks.

Category 2: Growth Hormone Optimization

CJC-1295 + Ipamorelin

Rating: Synergy
Reasoning: CJC-1295 (GHRH analog) primes somatotrophs to produce GH; Ipamorelin (GHS-R agonist) triggers release. Two signals, two pathways, one amplified pulse. Ipamorelin’s clean profile (no cortisol/prolactin elevation) makes it the ideal secretagogue partner.
Evidence: CJC-1295 has published human data (Teichman et al., 2006, JCEM — PubMed 16352683). Ipamorelin Phase II data. Combination is the most prescribed GH peptide protocol. See CJC-1295-Ipamorelin.
Protocol Notes: Can combine in same syringe. 100-300 mcg each, bedtime, fasted. 5 on/2 off. Monitor IGF-1.

CJC-1295 + GHRP-2

Rating: Caution
Reasoning: Mechanistically synergistic (GHRH + secretagogue), but GHRP-2 raises cortisol and prolactin, increases appetite significantly, and has less selective receptor binding than Ipamorelin. Higher side-effect burden.
Evidence: GHRP-2 human data exists. The combination works but is inferior to CJC-1295/Ipamorelin for most applications due to side effects.
Protocol Notes: If using, monitor cortisol, prolactin, and appetite. Lower doses recommended. Ipamorelin is preferred over GHRP-2 in nearly all cases.

CJC-1295 + GHRP-6

Rating: Caution
Reasoning: Same synergy logic as above, but GHRP-6 causes extreme hunger (ghrelin-like), raises cortisol/prolactin more than GHRP-2. Only appropriate when appetite stimulation is a goal (cachexia, underweight).
Evidence: Preclinical and limited clinical data. Known side-effect profile.
Protocol Notes: Reserve for cases where appetite stimulation is desired. Not recommended for body composition or fat loss goals.

CJC-1295/Ipamorelin + MK-677 (Ibutamoren)

Rating: Caution
Reasoning: MK-677 is an oral GH secretagogue with 24-hour duration. Adding it to CJC-1295/Ipamorelin risks supraphysiological GH/IGF-1 levels, insulin resistance, water retention, and carpal tunnel symptoms.
Evidence: MK-677 has published human data showing GH elevation but also glucose/insulin concerns. Stacking adds risk without proportional benefit.
Protocol Notes: If combining, reduce doses of all compounds and monitor IGF-1 and fasting glucose frequently. Generally not recommended — choose one GH strategy.

CJC-1295/Ipamorelin + Sermorelin

Rating: Neutral
Reasoning: Sermorelin is another GHRH analog. Adding it to CJC-1295 is redundant — both target the same GHRH receptor. No added benefit, just more cost.
Evidence: Sermorelin has FDA history (previously approved, discontinued). Mechanistic redundancy with CJC-1295.
Protocol Notes: Choose one GHRH analog, not both. CJC-1295 (Mod GRF) is generally preferred for potency and half-life.

Category 3: Cognitive / Neuropeptides

Semax + Selank

Rating: Synergy
Reasoning: Semax drives BDNF/neuroplasticity/focus; Selank provides GABA-mediated anxiolysis and emotional stability. Together: calm, focused cognitive enhancement without stimulant jitters or anxiolytic sedation.
Evidence: Both approved in Russia. Functional connectomic study (PubMed 32342318) examined both. Gene expression data for Selank’s GABAergic effects (PMC4757669). See Semax-Selank.
Protocol Notes: Intranasal preferred. 200-600 mcg Semax + 250-750 mcg Selank daily. 10-20 day cycles. Avoid evening Semax if sleep-disruptive.

Semax + Dihexa

Rating: Caution
Reasoning: Both enhance neuroplasticity — Semax via BDNF, Dihexa via HGF/c-Met pathway. Potentially synergistic for cognitive enhancement, but Dihexa has very limited safety data, extremely high potency (picomolar active), and unknown long-term risks.
Evidence: Dihexa published in one key paper (Benoist et al., 2014). Extremely limited human data. High-risk compound.
Protocol Notes: Advanced users only. Dihexa doses are extremely small (0.5-1 mg SubQ). If combining, start Dihexa at minimum effective dose. Not recommended without physician oversight.

Selank + DSIP

Rating: Synergy
Reasoning: Selank (anxiolytic, daytime) + DSIP (Delta Sleep-Inducing Peptide, nighttime) creates a 24-hour neurological optimization — calm focus during the day, deep restorative sleep at night.
Evidence: Both have Russian clinical use history. DSIP has limited but supportive sleep data. Commercial blends available (Semax/Selank/DSIP).
Protocol Notes: Selank AM/midday. DSIP 100-200 mcg SubQ 30 min before bed. Standard cycling applies.

Category 4: Mitochondrial / Energy

MOTS-c + SS-31

Rating: Synergy
Reasoning: MOTS-c signals mitochondrial biogenesis (AMPK activation); SS-31 stabilizes existing mitochondria (cardiolipin binding). One builds new, the other preserves existing. Complete mitochondrial strategy.
Evidence: SS-31 has FDA approval for Barth syndrome (2025). MOTS-c has preclinical metabolic data. See MOTS-c-SS-31-NAD.
Protocol Notes: MOTS-c: 5-10 mg 3-5x/week SubQ AM fasted. SS-31: 0.5-2 mg/day SubQ. 12-week cycles.

MOTS-c + 5-Amino-1MQ

Rating: Synergy
Reasoning: MOTS-c activates AMPK for energy metabolism; 5-Amino-1MQ preserves NAD+ by blocking NNMT. Both improve metabolic efficiency through non-overlapping pathways. MOTS-c tells cells to burn energy more efficiently; 5-Amino-1MQ ensures the NAD+ fuel is available.
Evidence: Individual preclinical data for both. No combination data. Logical metabolic synergy.
Protocol Notes: MOTS-c: 5-10 mg 3-5x/week. 5-Amino-1MQ: 50-100 mg/day oral. Align cycling (6 weeks on, 4 off).

SS-31 + NAD+ (NMN/NR)

Rating: Synergy
Reasoning: SS-31 stabilizes the ETC that uses NAD+ as electron carrier. NAD+ supplementation ensures substrate availability for the stabilized complexes. Without NAD+, even a perfectly functioning ETC has nothing to process.
Evidence: SS-31 clinical data (Phase II/III). NMN/NR clinical data for NAD+ elevation. Logical substrate-enzyme relationship.
Protocol Notes: SS-31: standard dosing. NMN: 500-1000 mg/day. Can run simultaneously without conflict.

Category 5: Immune Modulation

Thymosin Alpha-1 + KPV

Rating: Synergy
Reasoning: TA-1 trains adaptive immunity (T-cell maturation, Treg expansion); KPV calms innate inflammation (NF-kB inhibition). Addresses the autoimmune paradox: stronger immune surveillance with quieter inflammatory output.
Evidence: TA-1 approved in 35+ countries. KPV has preclinical anti-inflammatory data. See Thymosin-Alpha-1-KPV.
Protocol Notes: TA-1: 1.6 mg 2-3x/week SubQ. KPV: 500 mcg-1 mg daily. 12-week cycles. Zinc cofactor required.

Thymosin Alpha-1 + BPC-157

Rating: Synergy
Reasoning: TA-1 optimizes immune function; BPC-157 heals tissue damage from chronic immune dysregulation. Useful for post-viral recovery, mold illness, and chronic infections where both immune competence and tissue repair are needed.
Evidence: Individual evidence for both. Common clinical pairing in functional/integrative medicine.
Protocol Notes: Standard doses of each. Can run simultaneously. No timing conflicts.

Thymosin Alpha-1 + Immunosuppressants (Prednisone, MTX, Biologics)

Rating: Conflict
Reasoning: TA-1 enhances immune function; immunosuppressants suppress it. Directly antagonistic mechanisms. TA-1 could reduce effectiveness of immunosuppressive therapy or trigger immune flares.
Evidence: Mechanistic antagonism is clear. No clinical data on the specific interaction.
Protocol Notes: Do not combine without specialist oversight. If transitioning from immunosuppressants to peptide therapy, work with a physician experienced in both.

Category 6: Sexual Health

PT-141 + Kisspeptin

Rating: Synergy
Reasoning: PT-141 activates melanocortin-driven desire pathways in the brain; Kisspeptin drives the hormonal cascade (GnRH → LH/FSH → sex hormones). Two dimensions of sexual function: desire + hormonal foundation.
Evidence: PT-141 FDA-approved (Vyleesi, 2019). Kisspeptin has multiple clinical trials (Imperial College London). See PT-141-Kisspeptin.
Protocol Notes: PT-141: 1.75-2 mg as needed (pre-activity). Kisspeptin: 50-200 mcg 2-3x/week. Monitor BP and nausea.

PT-141 + Melanotan II

Rating: Caution
Reasoning: Both are melanocortin receptor agonists. Melanotan II is non-selective (MC1R-MC5R) vs PT-141’s MC4R selectivity. Combining amplifies side effects: nausea, facial flushing, hyperpigmentation, blood pressure effects. Overlapping receptor activation with no added specificity.
Evidence: Both have human use data. Side effect amplification is predictable from receptor pharmacology.
Protocol Notes: Not recommended. Choose one. PT-141 is preferred for sexual health (selective, FDA-approved). Melanotan II only if tanning is also a goal (and risk is accepted).

PT-141 + PDE5 Inhibitors (Viagra/Cialis)

Rating: Caution
Reasoning: Different mechanisms (central vs peripheral) but additive hemodynamic effects. PT-141 can transiently increase BP; PDE5 inhibitors lower BP. Combined cardiovascular effects unpredictable.
Evidence: PT-141 FDA labeling notes caution with antihypertensives. No specific combination study.
Protocol Notes: Physician oversight required if combining. Do not use on same day without medical guidance. Start with lower doses of each.

Kisspeptin + TRT/HRT

Rating: Caution
Reasoning: Kisspeptin stimulates endogenous hormone production (GnRH → LH/FSH → T/E). Exogenous TRT/HRT suppresses the HPG axis via negative feedback. Kisspeptin’s signal may be wasted on a suppressed axis. Potentially antagonistic or redundant.
Evidence: Mechanistic logic. No clinical data on the combination.
Protocol Notes: If on TRT, Kisspeptin is unlikely to add hormonal benefit. Consider Kisspeptin as a TRT alternative (HPG axis preservation) rather than an addition. Consult endocrinologist.

Category 7: Fat Loss / Metabolic

AOD-9604 + 5-Amino-1MQ

Rating: Synergy
Reasoning: AOD-9604 drives lipolysis via HGH 176-191 fragment mechanism; 5-Amino-1MQ blocks NNMT to preserve NAD+ and reprogram fat cell metabolism. Entirely different pathways — one breaks down fat, the other prevents fat storage and boosts metabolic rate.
Evidence: Individual preclinical data. No combination data. No documented negative interactions. See AOD-9604-5-Amino-1MQ.
Protocol Notes: AOD-9604: 300 mcg/day SubQ AM fasted. 5-Amino-1MQ: 50-100 mg/day oral. 6 weeks on, 4 off.

AOD-9604 + CJC-1295/Ipamorelin

Rating: Synergy
Reasoning: AOD-9604 handles direct fat loss; CJC-1295/Ipamorelin elevate GH for lean mass preservation and recovery. Complementary body composition goals — lose fat while preserving muscle.
Evidence: Individual clinical data. Common clinical pairing. No mechanistic conflict.
Protocol Notes: AOD-9604 AM fasted. CJC-1295/Ipamorelin bedtime fasted. Natural timing separation.

AOD-9604 + MK-677

Rating: Caution
Reasoning: MK-677 elevates GH but also increases appetite and can worsen insulin sensitivity. For fat loss, appetite stimulation and insulin resistance are counterproductive. AOD-9604’s fat-loss benefits may be offset by MK-677’s metabolic side effects.
Evidence: MK-677 human data shows glucose/insulin concerns. Mechanistic antagonism for fat loss goals.
Protocol Notes: Not recommended for fat loss. If using MK-677 for other goals, AOD-9604 may partially offset its fat-sparing effects.

5-Amino-1MQ + NAD+ (NMN/NR)

Rating: Synergy
Reasoning: 5-Amino-1MQ blocks NAD+ degradation (NNMT inhibition); NAD+ supplementation increases supply. “Fill the tub while plugging the drain.” Amplified NAD+ retention for metabolic and longevity benefits.
Evidence: Mechanistic synergy well-established. See 5-Amino-1MQ-NAD.
Protocol Notes: 5-Amino-1MQ: 50-100 mg/day. NMN: 500-1000 mg/day. Add TMG as methyl donor.

Category 8: Anti-Aging / Longevity

GHK-Cu + Epithalon

Rating: Synergy
Reasoning: GHK-Cu resets gene expression toward youthful patterns and rebuilds ECM; Epithalon activates telomerase to preserve cell replicative capacity. Two distinct aging mechanisms targeted: structural degradation + replicative senescence.
Evidence: GHK-Cu gene expression data (Pickart et al., multiple papers). Epithalon telomerase data (Khavinson et al.). See GHK-Cu-Epithalon.
Protocol Notes: Epithalon: 10-day bursts 2-4x/year. GHK-Cu: 8-12 week cycles. Different cycling patterns — coordinate per annual schedule.

Epithalon + NAD+

Rating: Synergy
Reasoning: Epithalon preserves telomeres (cellular lifespan); NAD+ supports sirtuin activity and mitochondrial function (cellular energy). Complementary longevity axes with no mechanistic overlap or conflict.
Evidence: Individual compound data. Logical anti-aging combination.
Protocol Notes: Standard dosing for each. No timing conflicts.

GHK-Cu + BPC-157

Rating: Synergy
Reasoning: Both promote tissue repair through different growth factor pathways. GHK-Cu drives ECM remodeling and collagen; BPC-157 drives angiogenesis and mucosal healing. Additive healing effects.
Evidence: Individual preclinical data. No combination data.
Protocol Notes: Standard doses. Both promote angiogenesis — cancer exclusion applies to the combination.

Category 9: Cross-Category Interactions

BPC-157 + CJC-1295/Ipamorelin

Rating: Synergy
Reasoning: BPC-157 heals tissue locally; GH elevation from CJC-1295/Ipamorelin supports systemic recovery and tissue regeneration. No mechanistic conflict. GH enhances collagen synthesis, complementing BPC-157’s growth factor effects.
Evidence: No conflict documented. Common clinical pairing for injury recovery + body composition.
Protocol Notes: BPC-157: timing flexible. CJC-1295/Ipamorelin: bedtime fasted. No interaction.

Semax/Selank + CJC-1295/Ipamorelin

Rating: Neutral
Reasoning: Different target systems (CNS vs endocrine). No interaction. Can run simultaneously for cognitive + body composition goals.
Evidence: No interaction data needed — distinct mechanisms and targets.
Protocol Notes: Standard doses of each. Semax intranasal AM. CJC-1295/Ipamorelin SubQ PM.

MOTS-c + CJC-1295/Ipamorelin

Rating: Neutral
Reasoning: MOTS-c targets mitochondrial/metabolic pathways; CJC-1295/Ipamorelin target GH axis. No overlap or conflict. Both support longevity through independent mechanisms.
Evidence: No interaction documented. Complementary longevity axes.
Protocol Notes: MOTS-c AM fasted. CJC-1295/Ipamorelin PM fasted. Natural timing separation.

KPV + Semax/Selank

Rating: Neutral
Reasoning: KPV is anti-inflammatory (gut/systemic); Semax/Selank are nootropic. No interaction. Can run simultaneously.
Evidence: Selank has mild immunomodulatory properties (tuftsin backbone), but no conflict with KPV’s NF-kB inhibition.
Protocol Notes: Standard doses. No timing conflicts.

TA-1 + CJC-1295/Ipamorelin

Rating: Neutral
Reasoning: Immune modulation and GH optimization are independent axes. GH has mild immune effects but at secretagogue doses, no meaningful interaction with TA-1’s targeted immune training.
Evidence: No interaction documented.
Protocol Notes: Standard doses. No timing conflicts.

BPC-157 + Semax

Rating: Neutral
Reasoning: BPC-157 has gut-brain axis effects (vagal modulation) and Semax is a neuropeptide. Theoretical synergy for neurological recovery, but no conflict at standard doses. Different primary targets.
Evidence: BPC-157’s CNS effects documented (PMC5333585). No combination data.
Protocol Notes: Standard doses. BPC-157 SubQ or oral. Semax intranasal. No interaction.

AOD-9604 + BPC-157

Rating: Neutral
Reasoning: Fat loss and tissue healing are independent goals. No mechanistic overlap or conflict.
Evidence: No interaction documented.
Protocol Notes: AOD-9604 AM fasted. BPC-157 timing flexible. Can run simultaneously.

Epithalon + Semax/Selank

Rating: Neutral
Reasoning: Telomere preservation and cognitive enhancement target different systems. No interaction.
Evidence: No interaction documented.
Protocol Notes: Standard doses. Epithalon SubQ evening. Semax/Selank intranasal AM.

PT-141 + BPC-157

Rating: Neutral
Reasoning: Sexual health and tissue healing are independent. No mechanistic overlap.
Evidence: No interaction documented.
Protocol Notes: Standard doses. No timing conflicts.

GHK-Cu + KPV

Rating: Synergy
Reasoning: GHK-Cu rebuilds tissue and collagen; KPV suppresses inflammation. For skin conditions, wound healing, or post-procedure recovery, the combination addresses both inflammation and structural repair.
Evidence: Individual compound data. Logical complementarity.
Protocol Notes: GHK-Cu: topical or SubQ. KPV: SubQ or oral. Standard doses.

Universal Conflict: Cancer Risk

ALL angiogenic, growth-promoting, or telomerase-activating peptides are contraindicated in active cancer:

Compound	Cancer Risk Mechanism
BPC-157	Angiogenesis (VEGF upregulation) — may vascularize tumors
TB-500	Cell migration promotion — may facilitate metastasis
GHK-Cu	Angiogenesis + cell proliferation signals
Epithalon	Telomerase activation — cancer cells use this for immortality
CJC-1295/Ipamorelin	IGF-1 elevation — promotes cell proliferation
MK-677	IGF-1 elevation (sustained, 24hr)
MOTS-c	AMPK activation — context-dependent effects on tumors (may be suppressive in some cases)

Rule: If cancer history, active malignancy, or significant cancer risk factors exist, consult an oncologist before using ANY peptide from the above list. Some peptides (TA-1) may be beneficial as cancer immunotherapy adjuvants, but this requires oncologist oversight.

Universal Caution: Stacking Multiple GH-Elevating Compounds

Combining multiple growth hormone secretagogues or analogs risks supraphysiological GH/IGF-1 levels:

Risk	Signs
Insulin resistance	Rising fasting glucose, HbA1c
Water retention	Edema, weight gain, puffy face
Carpal tunnel syndrome	Tingling, numbness in hands
Joint pain	Swelling, stiffness
Acromegaly-like features	Long-term risk at very high levels

Rule: Use ONE GH optimization strategy at a time. CJC-1295 + Ipamorelin is the preferred combination. Do not add MK-677, GHRP-2, GHRP-6, or Sermorelin on top without dose reduction and IGF-1 monitoring.

Timing Compatibility Quick-Reference

Compound	Optimal Timing	Fasting Required?
CJC-1295/Ipamorelin	Bedtime	Yes (2hr pre/post)
BPC-157	Any time	No
TB-500	Any time	No
Semax/Selank	Morning/midday	No
MOTS-c	Morning, fasted	Preferred
AOD-9604	Morning, fasted	Yes
PT-141	45-60 min pre-activity	No
Kisspeptin	Consistent schedule	No
TA-1	Morning	No
KPV (oral)	Empty stomach	Preferred
GHK-Cu	Any time	No
Epithalon	Evening	No
5-Amino-1MQ	Split AM/PM	No
NAD+ IV	Any time	No
DSIP	30 min before bed	No

Key Scheduling Principle: Fasting-required compounds (GH secretagogues, AOD-9604, MOTS-c) naturally separate into AM fasted or PM bedtime windows, preventing timing conflicts with non-fasting compounds.

Regulatory Status Summary (US)

Compound	Status	Sport Ban
BPC-157	Category 2 (FDA 2024)	WADA prohibited
TB-500	Research only	WADA prohibited
CJC-1295	Research only	WADA prohibited
Ipamorelin	Research only	WADA prohibited
Semax	Not approved (approved in Russia)	Not listed
Selank	Not approved (approved in Russia)	Not listed
MOTS-c	Research only	Not listed
SS-31	FDA-approved (Barth syndrome only)	Not listed
PT-141	FDA-approved (Vyleesi, HSDD)	Not listed
Kisspeptin	Investigational	Not listed
TA-1	Approved in 35+ countries (not US)	Not listed
KPV	Research only	Not listed
AOD-9604	Research only	WADA prohibited
5-Amino-1MQ	Research only	Not listed
GHK-Cu	Cosmetic/research	Not listed
Epithalon	Research only	Not listed
MK-677	Research only	WADA prohibited

This matrix reflects current understanding as of April 2026. Peptide research is rapidly evolving. All protocols should be supervised by a qualified healthcare provider. None of this constitutes medical advice.